3 ms·
20% of revenue is put back in R&D on average. Cut revenue, you cut R&D. And the US is about half of all global revenue, so half of all R&D expenses. The othe
by refurb 4y ago
20% of revenue is put back in R&D on average.
Cut revenue, you cut R&D.
And the US is about half of all global revenue, so half of all R&D expenses. The other 95% of the global population pays the other half.
- SonicTheSith1 4y ago20% goes into R&D, 30% goes into Marketing, 25% goes operating costs, 25% is profit. Since a lot of Pharma research is done at universities and is funded by the public, this holds true especially for insulin, maybe by cutting the costs of meds the companies optimise their system more. Less marketing, no Pharma people bribing doctors to use their meds etc. I bet if you cut those unnecessary jobs and expenses before touching R&D or Profit a lot can be done.
- refurb 4y ago30% doesn't go into marketing. And no, most pharma research is not funded by the public (the NIH budget is 1/4 what pharma spends).
- oblio 4y agoOr you know, they could, gasp cut lobbying expenses. Cut back on marketing (bribing doctors), cut back on admin overhead, cut back on... There are a million things they could cut back on. But the poor shareholders, would someone thing of the millionaires?!?
- dmitriid 4y ago> 20% of revenue is put back in R&D on average. Cut revenue, you cut R&D. 34% of money spent on healthcare is administrative overhead. Cut that, and you'll still have plenty of money for R&D https://pubmed.ncbi.nlm.nih.gov/31905376/ https://pubmed.ncbi.nlm.nih.gov/31905376/